925240-48-8

Upstream product

• 109183-71-3 N-(tert-butoxycarbonyl)-L-cyclohexylglycine 
• 107202-38-0 tert-butyl (S)-(methoxycarbonyl)(cyclohexyl)methylcarbamate 
• 145618-11-7 (S)-amino(cyclohexyl)acetic acid methyl ester 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 20859-02-3 L-tert-Leucine 
• 862118-90-9 tert-butyl (S)-1-((S)-(methylcarbamoyl)(cyclohexyl)methylcarbamoyl)-2,2-dimethylpropylcarbamate 
• 862119-00-4 (S)-((S)-2-tert-butoxycarbonylamino-3,3-dimethylbutyrylamino)cyclohexylacetic acid methyl ester 
• 862119-02-6 (S)-2-amino-N-((S)-cyclohexyl(methylcarbamoyl)methyl)-3,3-dimethylbutyramide 

Relevant academic research and scientific papers

Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: Discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-l-hydroxyproline bioisostere

Potent tetrapeptidic inhibitors of the HCV NS3 protease have been developed incorporating 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a new N-acyl-l-hydroxyproline mimic. The hydroxycyclopentene template was synthesized in eight steps from commercially available (syn)-tetrahydrophthalic anhydride. Three different amino acids were explored in the P1-position and in the P2-position the hydroxyl group of the cyclopentene template was substituted with 7-methoxy-2-phenyl-quinolin-4-ol. The P3/P4-positions were then optimized from a set of six amino acid derivatives. All inhibitors were evaluated in an in vitro assay using the full-length NS3 protease. Several potent inhibitors were identified, the most promising exhibiting a Ki value of 1.1 nM.